Metformin Testing Prompts New Finding Of NDMA And Cancer Risk
FDA Asks Several Manufacturers To Recall Products In US
Executive Summary
The US FDA requests several manufacturers recall extended-release metformin based on studies confirming a higher NDMA impurity threshhold; previous testing found no significant risks.
You may also be interested in...
Pharmacy Calls For The FDA To Require Independent Third-Party Testing
An online pharmacy that tests medications before dispensing them advocated for regulations requiring independent testing and verification of the chemical content of pharmaceuticals; it also alleged that the US FDA’s testing method for evaluating the carcinogenic risk of metformin needs refinement.
US FDA Finds Negligible Cancer Risks In Metformin Products
The US FDA finds metformin meets NDMA impurity threshold and urges diabetics to continue taking it.
US FDA Finds Zantac Poses Little Risk, But Concerns Linger
Ranitidine no more carcinogenic than grilled meat, the FDA’s Woodcock says, with NDMA levels well below those claimed by Valisure.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Generics Bulletin?
Request a free trial today!
Register for our free email digests:
Register for our free email digests: